Targeting Ion Channel TRPM4

Barbara Preti; Jean-Sébastien Rougier; Irida Papapostolou; Florian Bochen; Christian E. Gerber; Hugues Abriel; Martin Lochner; Christine Peinelt

doi:10.2533/chimia.2022.1039

Authors

Barbara Preti Institute if Biochemistry and Molecular Medicine, University of Bern https://orcid.org/0000-0002-6810-6763
Jean-Sébastien Rougier Institute of Biochemistry and Molecular Medicine, University of Bern
Irida Papapostolou Institute of Biochemistry and Molecular Medicine, University of Bern
Florian Bochen Institute of Biochemistry and Molecular Medicine, University of Bern
Christian E. Gerber Institute of Biochemistry and Molecular Medicine, University of Bern https://orcid.org/0000-0002-5517-4951
Hugues Abriel Institute of Biochemistry and Molecular Medicine, University of Bern https://orcid.org/0000-0003-0465-5138
Martin Lochner Institute of Biochemistry and Molecular Medicine, University of Bern https://orcid.org/0000-0003-4930-1886
Christine Peinelt Institute of Biochemistry and Molecular Medicine, University of Bern https://orcid.org/0000-0002-3474-6893

DOI:

https://doi.org/10.2533/chimia.2022.1039

PMID:

38069800

Keywords:

Cancer, Cardiac disease, TRPM4, Small-molecule inhibitors

Abstract

The transient receptor potential melastatin 4 (TRPM4) ion channel is ubiquitously expressed. Dysregulation and/or functional mutations of TRPM4 lead to several diseases. Within our studies, we screened for TRPM4 inhibitors and identified small molecules that block TRPM4 in the low µM range. Furthermore, we investigated the pathophysiology of TRPM4 in cardiac conditions, immune diseases and cancer using these novel inhibitors, molecular biology techniques and functional assays.

Targeting Ion Channel TRPM4

Authors

DOI:

PMID:

Keywords:

Abstract

Downloads

Published

Issue

Section

License

How to Cite

Make a Submission

oa

socialmedia

Follow CHIMIA on Social Media

Sections

Information

Latest publications